ABMD News and Press, ABIOMED Inc. From 02/03/21

Moleculin Biotech (MBRX) -21% on launch of public offering.NTN Buzztime (NTN) -16%.PEDEVCO (PED) -13% after pricing stock offering.Ocugen (OCGN) -14%.Voyager Therapeutics (VYGR) -13% on termination of Parkinson’s collaboration with Neurocrine Bio.Titan Med...

When most of us think of coronavirus stocks, we think of vaccine makers or companies developing therapeutics. We probably don't think of medical device players specializing in heart pumps. Since June, hospitals have been using Abiomed 's (NASDAQ: ABMD) heart pumps to help COVID-...

In addition to vaccines, it is now the turn of antibodies treatment to play a role in fighting COVID. There are also the diagnostics developers that still have an important stake in enabling recovery in intercontinental travel through rapid testing. Political challenges remain but...

Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at explant. A majority of surviving patients recovered their native heart function without needing further mechanical ...

On Thursday morning, medical devices specialist Abiomed (NASDAQ: ABMD) released its financial reports for the third quarter of its fiscal year 2021, which ended on Dec. 31, 2020. Investors seem to be happy with the company's performance during this quarter: Abiomed's stock is up by ...

Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q3 2021 Earnings Call Jan 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Abiomed Inc (ABMD) Q3 2021 Earnings Call Transcript

Abiomed, Inc. (ABMD) Q3 2021 Earnings Conference Call January 28, 2021, 08:00 AM ET Company Participants Michael Minogue - Chairman, President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Raj Denhoy - Jefferies Matthew O'Brie...

Abiomed (ABMD) FQ3:Revenue: $231.7M (+4.6%).Worldwide Impella® heart pump revenue: $220.8M (+4%).Operating income: $71.4M (+2%).Gross margin: 82.3% vs 82% last year.Operating cash flow: $79.1MFQ4 revenue outlook: To be in the range of $225M to $235MOn January 7, the c...

The following slide deck was published by Abiomed, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Abiomed, Inc. 2021 Q3 - Results - Earnings Call Presentation

Abiomed (ABMD): FQ3 Non-GAAP EPS of $1.17 beats by $0.07; GAAP EPS of $1.35 beats by $0.23.Revenue of $231.7M (+4.6% Y/Y) beats by $5.39M.Press Release For further details see: Abiomed EPS beats by $0.07, beats on revenue